December 6-8, 2022 | Boston, MA

Navigate through Novel Viruses, Rational Combination Regimens, Optimized Virus Delivery & Clinical Grade Manufacturing to Make OV an Established Modality of Cancer Immunotherapy.

With rapid advances in this compelling  therapeutic, the 7th Virotherapy Summit returns to Boston this December. With IV-delivery now reaching the late preclinical stage, IT-delivery continuing to hold its ground within the clinic, and new combinations emerging there has never been a more exciting time for the oncolytic virotherapy community to come together.

Bringing together 100+ trailblazing biotech’s, pioneering large pharma, oncology-focused drug developers, VCs and financial investors to discuss:

• Novel translational and combination data
• CMC, Manufacturing & regulatory requirements
• Partnering and licensing aspects
• Optimizing both IV- and IT-based delivery

Join us at the world’s only true end-to-end OV summit as we finally realize the promise of oncolytic viruses.

Register today to join us in Boston this December.